1 Torre L A,Bray F,Siegel R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108. 2 Wang S,Chen A,Yang L,et al.Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome[J].Sci Rep,2018,8(1):10393. 3 Angarita F A,Acuna S A,McCready D R,et al.Management of positive margins after initial lumpectomy in elderly women with breast cancer[J].Eur J Surg Oncol,2018,44(7):1048-1053. 4 Chae H,Yoo C,Yoon J A,et al.FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment[J].J Breast Cancer,2018,21(1):45-50. 5 李春艳,苏薇,张晟,等.细胞周期调控基因对局部晚期乳腺癌新辅助化疗疗效的影响[J].中华医学杂志,2017,97(34):2682-2686. 6 韦立群,徐成飞,李婉婷,等.NF-κB和MAPK信号通路参与金雀异黄酮诱导乳腺癌MDA-MB-231细胞凋亡的体外研究[J].中国药理学通报,2018,34(5):690-694. 7 Wang J,Sun P,Chen Y,et al.Novel 2-phenyloxy-pyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells[J].Sci Rep,2018,8(1):10923. 8 Weiss A,King T A,Hunt K K,et al.Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System:Review of the Supporting Evidence[J].Surg Clin North Am,2018,98(4):687-702. 9 刘进平,夏勇,李进,等.血浆游离mtDNA及脑组织TLR-9/MAPK的表达在蛛网膜下腔出血中的意义[J].四川大学学报(医学版),2017,48(2):225-229. 10 Borelli B,Moretto R,Lonardi S,et al.TRIPLETE:a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer[J].ESMO Open,2018,3(4):000403. 11 李林,朱明智,王楠,等.免疫抑制作用对三阴性乳腺癌化疗作用的影响[J].中华实验外科杂志,2017,34(4):568-571. 12 刘夏,浦春,黄丽珠.乳腺癌相关miRNA的研究进展[J].临床输血与检验,2017,19(4):413-416. 13 Huang Y,Cai G Q,Peng J P,et al.Glucocorticoids induce apoptosis and matrix metalloproteinase-13 expression in chondrocytes through the NOX4/ROS/p38 MAPK pathway[J].J Steroid Biochem Mol Biol,2018,181:52-62. 14 梁红玲,黄健清,金田恩,等.BIM缺失多态性与乳腺癌紫杉醇内源性耐药机制的关系[J].实用医学杂志,2018,34(4):531-534. 15 Bai X,Ni J,Beretov J,et al.Cancer stem cell in breast cancer therapeutic resistance[J].Cancer Treat Rev,2018,69:152-163. 16 齐宇新,刘姣,何颖娜,等.乳腺癌术后蒽环类化疗药物致心脏损害的早期监测分析[J].中国药房,2017,28(17):2356-2359. 17 仇爱峰,苗志龙,葛国侃,等.蒽环联合或序贯紫衫类不同给药间期对Luminal B型乳腺癌新辅助化疗疗效的影响[J].中华医学杂志,2017,97(44):3466-3470. 18 Mazzuca F,Onesti C E,Roberto M,et al.Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines[J].Oncotarget,2018,9(39):25714-25722. 19 凌琼颖,赵爱峡,谢晓楠,等.长春瑞滨联合铂类治疗蒽环和紫杉类耐药的转移性乳腺癌的临床研究[J].广西医科大学学报,2017,34(12):1717-1720. 20 王晶晶,彭博,贺蓉,等.筋骨草和茯苓配伍合用抑制乳腺癌细胞侵袭转移作用及初步机制研究[J].中国药理学通报,2017,33(4):581-588. 21 Zhang T,Jiang K,Zhu X,et al.miR-433 inhibits breast cancer cell growth via the MAPK signaling pathway by targeting Rap1a[J].Int J Biol Sci,2018,14(6):622-632. 22 Luo G,Tang Z,Lao K,et al.Structure-activity relationships of 2,4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity[J].Eur J Med Chem,2018,150:783-795. |